Grey
Brand Name(s):Provenge
Indication:Prostate cancer metastatic, hormone-refractory
Rationale:1
Considered:Apr-07
Review Date:Mar-20
Comments:
NICE TA 332
Treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer. Full guidance at:
https://www.nice.org.uk/guidance/ta332/resources/guidance-sipuleucelt-for-treating-asymptomatic-or-minimally-symptomatic-metastatic-hormonerelapsed-prostate-cancer-pdf
February 2015